NeoDynamics – Presentation of Annual Accounts 2022
NeoDynamics had a very busy 2022 and ready to launch Neonavia in US - 2023.
Medtech company NeoDynamics got FDA approval for Neonavia in US early fall 2022 and they are now ready for full commercialization of NeoNavia in US - 2023.
NeoDynamics have a very strong patent portfolio in major European markets, China, and US. It is the company’s vision that NeoDynamics pulse technology becomes the new standard for all ultrasound-guided breast cancer biopsies, improving both precision and reliability, and contributing to correct diagnoses and enable individualised treatment without delays for every individual breast cancer patient.
"The NeoNavia biopsy system can safely increase the precision of ultrasound-guided, technically challenging biopsies such as in axillary lymph nodes."
Meet CFO Aaron Wong the 20th of February 2023 at 1PM when he presents the Annual Accounts. As always you are more than welcome to post questions during the presentation.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup, 1:15 PM 17 January 2023